Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

Recruiting now · Not applicable

Conditions studied: Whole Genome Sequencing, Acute Myeloid Leukemia, Myelodysplastic Syndromes

In brief

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Key facts

Study ID
NCT04986657
Run by
Washington University School of Medicine
People needed
325
Starts
2021-09-17
Expected to finish
2027-12-31
Last updated by the study team
2025-10-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.